C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 123 filers reported holding C4 THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $748,700 | -52.2% | 402,527 | -29.3% | 0.00% | -50.0% |
| Q2 2023 | $1,564,967 | +89.3% | 569,079 | +116.2% | 0.00% | +100.0% |
| Q1 2023 | $826,649 | +18.5% | 263,264 | +122.6% | 0.00% | 0.0% |
| Q4 2022 | $697,823 | -59.4% | 118,275 | -39.6% | 0.00% | -66.7% |
| Q3 2022 | $1,717,000 | -31.8% | 195,759 | -41.4% | 0.01% | -25.0% |
| Q2 2022 | $2,518,000 | -9.7% | 333,891 | +190.5% | 0.01% | 0.0% |
| Q1 2022 | $2,788,000 | +196.0% | 114,931 | +445.4% | 0.01% | +300.0% |
| Q3 2021 | $942,000 | +127.0% | 21,073 | +92.0% | 0.00% | +100.0% |
| Q2 2021 | $415,000 | – | 10,973 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |